Alcaftadine: Selective Separation and Characterization of Degradation Products by LC–QTOF-MS/MS
A rapid, precise and accurate gradient UPLC method was developed for the selective separation of degradation products of alcaftadine. Forced degradation studies of the drug were carried out by examining factors suggested by ICH guidelines. The degradation products were formed in acidic, alkaline and peroxide conditions; however, the drug was stable in neutral, thermal and photolytic degradation conditions. The chromatographic separation of the degradation products and the drug was carried out using an ACQUITY CSH C18 (100 × 2.1 mm, 1.7 µm) column and a mixture of ammonium acetate buffer (10 mM, pH 5.0) and methanol was used as mobile phase. The UPLC method was extended to UPLC–quadrupole time-of-flight tandem mass spectrometry for the characterization of the degradation products. Detection was achieved by PDA at 284 nm. The proposed method can be used in quality control for the determination of impurities of alcaftadine and for its stability studies. The developed method was validated in terms of specificity, linearity, accuracy, precision and robustness according to the ICH guidelines.
KeywordsLC–QTOF-MS/MS Alcaftadine Characterization Forced degradation Validation
The authors thank the Project Director, NIPER Hyderabad, and Director, IICT, Hyderabad, for their support. The authors are thankful to the Department of Pharmaceuticals, Minister of Chemicals and Fertilizers, Govt. of India, for providing research fellowships.
Compliance with Ethical Standards
Conflict of interest
The authors declare that there is no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Greiner JV, Edwards-Swanson K, Ingerman A (2011) Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 5:87Google Scholar
- 3.Chemistry Review, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022134s000ChemR.pdf. Accessed 16 Mar 2015)
- 4.Mishra PR, Inamdar P, Jamdar P, Patel N, Rohit M, Satone D, Meshram DB (2015) Development and validation of UV-spectrophotometry and the first order derivative using the area under curve method for the estimation of alcaftadine in bulk and its ophthalmic dosage form. FS J Pharm Res 4(1):9–13Google Scholar
- 5.ICH guideline (1996) Q1B photostability testing of new drug substances and products, International Conference on Harmonisation, IFPMA, Geneva, SwitzerlandGoogle Scholar
- 6.ICH guideline (2003) Q1A (R2) Stability Testing of New Drug Substances and Products, International Conference on Harmonisation, IFPMA, Geneva, SwitzerlandGoogle Scholar
- 12.Karen MA, Linda M, Baertschi SW (2003) Stress testing benchmarking study. Pharm Technol 27:60–72Google Scholar
- 17.International Conference on Harmonization, IFPMA (2005) Validation of analytical procedures: text and methodology. Q2 (R1), International Conference on Harmonization, IFPMA, Geneva, SwitzerlandGoogle Scholar
- 18.Lukulay P, Hokanson G (2005) Reconciling mass balance in forced degradation studies. Pharm Tech 29(10):106–112Google Scholar